DEA Rescheduling Bet May Leave THCA Hemp Loophole Wide Open

The Rescheduling Gamble

Rescheduling marijuana to Schedule III doesn't alter the Farm Bill's definition of hemp, which measures only delta-9 THC by dry weight and ignores total THC or THCA content. The DEA's proposed rule, currently in its public comment window through August 2026, focuses narrowly on moving cannabis and its derivatives from Schedule I to Schedule III under the Controlled Substances Act. That shift would allow FDA-approved cannabis medicines and enable limited research access. But it does nothing to close the gap created when Congress legalized hemp in 2018.

The 2018 Farm Bill defined hemp as any cannabis plant containing no more than 0.3% delta-9 THC on a dry-weight basis. THCA — the non-intoxicating acid precursor that converts to delta-9 THC when heated — isn't measured in that formula. Cultivators have flooded retail channels with THCA flower that tests compliant as hemp but delivers the same psychoactive effect as Schedule I marijuana once smoked or vaped.

Rescheduling cannabis doesn't fix that. It may entrench it.

Why Schedule III Leaves the Loophole Intact

Moving cannabis to Schedule III affects only substances explicitly scheduled under the CSA; the Farm Bill operates on a separate statutory track that the DEA rule doesn't amend. Legal experts note that unless Congress rewrites the hemp definition to account for total THC or THCA, the loophole persists regardless of where marijuana sits on the schedule.

Delta-8 THC, delta-10, THC-O, and other semi-synthetic cannabinoids derived from CBD also remain in legal gray zones. The DEA has argued that synthetically derived THC isomers are controlled substances, but enforcement has been inconsistent and no court has definitively resolved the question. Rescheduling marijuana to Schedule III doesn't clarify the status of these compounds.

Regulators appear to be betting that rescheduling will satisfy political pressure for reform while avoiding the harder fight over hemp. That calculus may be wrong. Industry observers warn that leaving intoxicating hemp products unregulated while partially legitimizing medical marijuana creates a two-tier system with no coherent policy rationale.

State Enforcement Remains the Wild Card

Even if federal rescheduling proceeds, state-level bans on THCA and delta-8 products continue to proliferate, creating a patchwork that rescheduling does nothing to resolve. At least 18 states have moved to restrict or ban THCA flower and semi-synthetic cannabinoids since 2024, according to tracking by the Hemp Roundtable. Those bans operate independently of the CSA schedule. They'll remain in force whether cannabis is Schedule I or Schedule III.

States with adult-use marijuana programs have been the most aggressive in closing the hemp loophole, viewing THCA flower as untaxed competition that undercuts regulated dispensaries. States without legal cannabis programs have moved more slowly, in part because hemp-derived products provide the only legal access to intoxicating cannabinoids for consumers in those jurisdictions.

What Rescheduling Actually Changes

Schedule III status would allow cannabis businesses to deduct ordinary expenses under Section 280E of the tax code and enable expanded clinical research, but it wouldn't legalize recreational sales or resolve banking access issues. The immediate financial benefit accrues to multi-state operators and licensed medical dispensaries, which currently face effective tax rates above 70% due to the 280E prohibition on deducting business expenses for Schedule I or II substances.

Banking reform requires separate legislation. The SAFE Banking Act has stalled repeatedly in Congress, and rescheduling alone doesn't remove cannabis from the federal list of controlled substances — it just moves it to a lower tier. Financial institutions remain wary of serving cannabis clients without explicit safe-harbor language from Congress or the Treasury.

For context on the broader rescheduling timeline and stakeholder positions, see the CannIntel topic hub on DEA rescheduling.

The Chemistry That Matters

THCA converts to delta-9 THC through decarboxylation at approximately 220°F, a process that occurs instantly during smoking or vaping. A hemp flower testing at 0.25% delta-9 THC and 20% THCA is fully compliant with the Farm Bill's definition, yet it delivers roughly the same intoxicating dose as a dispensary product once combusted. The conversion ratio is close to 1:1 after accounting for molecular weight differences. Total potential THC is the more relevant measure for consumer safety and intoxication risk.

Federal agencies have acknowledged the problem but taken no coordinated action. The USDA, which oversees hemp cultivation, has proposed but not finalized a rule requiring testing for total THC. The FDA, which regulates hemp-derived consumables, has issued warning letters but no comprehensive enforcement framework. The DEA's rescheduling proposal doesn't address hemp at all.

What Happens Next

The DEA's comment period on rescheduling closes in August 2026, with a final rule expected by late 2026 or early 2027. Even if the rule is finalized, legal challenges are likely. Implementation timelines remain uncertain. Meanwhile, THCA flower and delta-8 products continue to proliferate in smoke shops, gas stations, and online retailers with no federal oversight.

This policy incoherence is unsustainable. Either Congress will have to revisit the Farm Bill's hemp definition, or states will continue to fragment the market with conflicting local bans. Rescheduling marijuana may score a political win, but it doesn't solve the harder problem: how to regulate intoxicating cannabinoids in a way that makes sense across the entire supply chain.

Expect enforcement to vary. This is unsettled.